Focused to development of efficient continuous bioprocesses for manufacture of biosimilar therapeutic molecules, Sudhin Biopharma Company is using high cell density continuous perfusion bioreactors and continuous chromatography / downstream processing techniques. The team has experience in Recombinant Protein Overexpression in (i) microbial hosts (E. coli, Pichia, etc.) and (a) fed-batch cultures and (ii) mammalian cells (e.g. CHO) (b) continuous perfusion cultures. The firm's biological manufacturing technology enables production of off-patent biological drugs more efficiently compared to the current biological manufacturing technologies. The firm is working on development of an efficient high cell density continuous manufacturing process for a biosimilar insulin analog, Lantus - off-patent in 2015. This and other insulin analogs, such as Lispro and Aspart, are very simple biological molecules and can be thoroughly characterized to be identical to the innovator drugs.
